Drug Profile


Alternative Names: BAM-002; Cisplatin/glutathione; Glutathione/cisplatin - Novelos Therapeutics; Glutoxim; NOV-002

Latest Information Update: 02 Apr 2014

Price : $50

At a glance

  • Originator BAM
  • Developer BAM; Cellectar Biosciences; Novelos Therapeutics
  • Class Oligopeptides; Platinum complexes
  • Mechanism of Action Immunomodulators; Protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Cancer
  • Suspended Breast cancer; Ovarian cancer; Radiation injuries
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 11 Feb 2014 Novelos Therapeutics is now called Cellectar Biosciences
  • 11 Apr 2011 Suspended - Preclinical for Radiation injuries in USA (Parenteral)
  • 11 Apr 2011 Suspended - Phase-II for Ovarian cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top